More than 300 million people in the world suffer from seasonal asthma to different degrees. The situation is more serious in seriously polluted countries and regions where tobacco consumption is high. Asthma and allergic rhinitis are common diseases in today’s world whose incidence has kept increasing every year due to nowadays’ severe air pollution.
Montelukast, developed by Merck, has been widely applied to the treatment of allergic rhinitis and asthma. Montelukast, a selective cysteinyl leukotriene receptor D4 antagonist, selectively combines with leukotriene in the airway and blocks the action of anaphylactic mediator so as to improve respiratory inflammation and keep airway open.
In 1998, Montelukast sodium tablets (10mg) and chewable tablets (5mg) first came into America’s market on FDA’s approval with a trade name of Singulair. In 2000 and 2002, Montelukast chewable tablets (4mg) and Montelukast granules (4mg) were approved to enter the market successively for the prevention and long-term treatment of asthma of adults and children aged at 2 or above 2.
After Singulair’s US patent expired on Aug.3, 2012, FDA has approved the generic drug applications of over 10 drug makers, among which Teva introduced tablets, chewable tablets and oral granules while Dr. Reddy’s introduced tablets and chewable tablets.
In 1999, Montelukast chewable tablets (5mg) and tablets(10mg) came into Chinese market on approval with a trade name of Singulair. Later, Montelukast chewable tablets (4mg) and granules(4mg) came into Chinese market on approval successively. The generic drugs of Montelukast tablets (10mg) and chewable tablets(5mg) made by Sichuan Otsuka was approved to enter the market in 2006 with a trade name of Bystine. Besides, there are also many other companies declaring generic drug in Chinese market.
According to CRI’s survey on some sample hospitals in China, the annual sales CAGR of Montelukast in Chinese hospitals exceeded 45% during the period of 2005-2010. With the appearance of some competitive products, the increase of Montelukast in Chinese market has slowed since 2011, but still remaining an annual growth of over 10%. Its sales CAGR still reached 25.5% during the period of 2010-2014.
It has been shown that China has more than 30 million asthma patients and 300-400 million patients suffering from allergic rhinitis. As the environmental pollution worsens in China, the number of patients will keep going up. In China, Montelukast is regarded as one of the most effective antiasthmatic drugs and therefore is estimated to enjoy huge market potential.
Readers can get at least the following information from this report:
-incidence of respiratory ailments in China
-Montelukast’s price in Chinese hospitals
-the production status of generic drugs of Montelukast in China
-major Montelukast manufacturers and their market share in China
-Market outlook of Montelukast in China
The author suggests the following groups of people purchase this report:
-manufacturers of Montelukast APIs and finished medicines
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese market of Montelukast or other medicines, please contact CRI for customized research service